At the news
? NEUTRALIMPACT 4/10 8-K filed May 7, 2026 at 16:01 ET
Corvus Pharmaceuticals reported Q1 2026 net loss of $13.7M ($0.15/share), slightly missing consensus of $0.14 loss. The miss is marginal and overshadowed by positive pipeline progress: soquelitinib Phase 2 AD trial initiation, ongoing Phase 3 PTCL enrollment, and upcoming SID data presentation on May 14.
- Net loss per share $0.15 vs consensus $0.14 (7.1% miss)
- Cash, cash equivalents and marketable securities $236.7M as of March 31, 2026
- Phase 2 atopic dermatitis trial initiated in Q1 2026
- Registrational Phase 3 PTCL trial enrollment continues
Before · The news · First close · A day later · A week later
Replay the market's reaction
Step through every 5 minutes around the news, then see how it compares with similar events.
Subscribe for Full Access